SCHEMBL6487775

SCHEMBL6487775

CC1CC2CCN1C[C@@H]2NC(=O)c1ccc(-c2cccc(Cl)c2)o1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.50
SMN1; SMN2 Q16637 6/20 0.50
RAB9A P51151 5/20 0.50
NPC1 O15118 4/20 0.50
MAPT P10636 4/20 0.50
KDM4E B2RXH2 3/20 0.50
LMNA P02545 1/20 0.50
HPGD P15428 4/20 0.48
MEN1 O00255 1/20 0.48
PRKD3 O94806 1/20 0.48
KMT2A Q03164 1/20 0.48
PRKD1 Q15139 1/20 0.48
PRKD2 Q9BZL6 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
S1PR4 O95977 1/20 0.48
GAA P10253 2/20 0.46
POLB P06746 2/20 0.45
MAPK1 P28482 3/20 0.45
PKM P14618 1/20 0.43
PDE4B Q07343 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6490046 0.90 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2RAB9ANPC1MEN1
SCHEMBL6488858 0.90 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6487435 0.89 NR4A1 (0.46) ALDH1A1RAB9ANPC1MAPTLMNA
SCHEMBL6500251 0.89 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6487200 0.89 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6499492 0.88 NPC1 (0.54) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6497753 0.88 ALDH1A1 (0.52) ALDH1A1RAB9ANPC1MAPTKDM4E
SCHEMBL6491368 0.87 NQO2 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL6491297 0.84 HDAC1 (0.47) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT
SCHEMBL4201068 0.84 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2RAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US claimed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US claimed
US-6919359-B2 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PFIZER INC (US) 2005-07-19 US disclosed
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease PHARMACIA & UPJOHN COMPANY 2003-11-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030207913-A1 Azabicyclic-substituted-heteroaryl compounds for the treatment of disease MALT1, WFS1, NR5A1 ALDH1A1 625/4885SMN1; SMN2 1751/4885RAB9A 1437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.